HEM — Hemostemix Income Statement
0.000.00%
Last trade - 00:00
- CA$4.36m
- CA$8.27m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 6.42 | 4.7 | 7.55 | 6.66 | 4.58 |
Operating Profit | -6.42 | -4.7 | -7.55 | -6.66 | -4.58 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.18 | -4.87 | -7.77 | -6.54 | -4.75 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.18 | -4.87 | -7.77 | -6.29 | -5.24 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -6.19 | -4.87 | -7.77 | -6.29 | -5.24 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.19 | -4.87 | -7.77 | -6.29 | -5.24 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.414 | -0.324 | -0.238 | -0.109 | -0.075 |